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ABSTRAK
Tujuan: untuk menentukan distribusi polimorfisme genetik PRMT-1 dan kadar ADMA pada pasien 
hemodialisis berkelanjutan. Metode: genotyping polimorfisme PRMT-1 dilakukan pada 57 pasien hemodialisis 
di Rumah Sakit Al-Irsjad. Semua partisipan menjalani pemeriksaan fisik, mengisi kuesioner dan pengambilan 
darah vena 5ml. Darah kemudian diekstraksi dengan menggunakan kloroform. Pemeriksaan single nucleotide 
polymorphism (SNPs) dilakukan dengan polimerase chain reaction-restriction fragment length polymorphism 
(PCR-RFLP). Kadar ADMA diukur menggunakan ELISA dan pemeriksaan petanda kimia klinik serum. 
Hasil: penelitian ini diikuti 57 pasien yang menjalani hemodialisis, 54 (95,4%) pasien tersebut mengalami 
kenaikan kadar ADMA. Dilakukan sekuensing DNA pada 13 pasien dan menunjukkan dugaan polimorfisme gen 
PRMT-1 pada titik 5837, karena pada titik tersebut ada perbedaan genotip C dan G. Kesimpulan: polimorfisme 
gen PRMT-1 diduga menjadi salah satu penyebab peningkatan kadar ADMA.
Kata kunci: ADMA, PRMT-1, polimorfisme, penyakit ginjal kronis.
ABSTRACT
Aim: to determine the distribution of PRMT-1 gene polymorphism and ADMA levels among continuing 
hemodialysis patients. Methods: genotyping of PRMT-1 polymorphism was performed in 57 hemodialysis 
patients at Al Irsjad Hospital. All participants were recruited for physical examination, questionnaire, and 
collection of 5 mL fasting venous blood. The blood was treated with phenol-chloroform extraction of genomic 
DNA. The candidate’s single nucleotide polymorphisms (SNPs) were genotyped by using polymerase chain 
reaction-restriction fragment length polymorphism (PCR-RFLP). The ADMA plasma levels was determined 
by ELISA and all biochemical indicators of serum were examined. Results: fifty-seven hemodialysis patients 
participated in our study, 54 (95.4%) of them had increased ADMA plasma levels. DNA sequencing analysis of 
13 patients showed a suspected PRMT-1 gene polymorphism at sequence 5837 as there were different genotypes 
between C and G. Conclusion: the increased levels of ADMA might be caused by PRMT-1 gene polymorphism.
Key words: ADMA, PRMT-1 polymorphism, chronic kidney disease.
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INTRODUCTION
Various research evidences suggest that 
renal dysfunction is associated with a high risk 
of cardiovascular disease (CVD) complications. 
Chronic kidney disease (CKD) has been 
considered to be a risk factor for CVD. As 
endothelial dysfunction is an early stage of 
atherosclerosis in patients with hypertension, 
diabetes and CKD, the decline in the availability 
of nitric oxide (NO) is considered as an 
independent risk factor for CVD among those 
patients.1
Previous studies have shown that endothelial 
dysfunction may predict the current and future 
CVD.2 Decreased availability of NO is closely 
related to the asymmetric dimethyl arginine 
(ADMA), an inhibitor of NOS.3 ADMA is 
an independent risk factor for atherosclerosis 
progression, death due to CVD and all causes 
of mortality.2 The increase of ADMA in animal 
studies increased blood pressure.4 Moreover, 
in endothelial cell culture of patients with 
CKD who had increased ADMA levels, it is 
found that ADMA significantly inhibits NO 
production.5 Several recent studies have shown 
that concentrations of ADMA in CKD patients, 
even at stage 1, has increased.3,6,7 Moreover, 
decreased levels of ADMA during hemodialysis 
is associated with improved endothelial function 
in patients with end-stage kidney disease.1
ADMA is produced about 300 mmol per 
day. Dimethyl arginine was obtained from the 
degradation of protein methylation product 
and produced by the protein methyl transferase 
(PRMT) enzymes. Currently, there are 9 genes 
of PRMT enzymes, which can be divided into 
2 groups: PRMT type I (1-4, 6 and 8) that 
produce ADMA and L-NMMA, and PRMT type 
II (5, 7, 9) that produce Symmetric Dimethyl 
Arginine (SDMA) and L-NMMA. Meanwhile, 
90% ADMA degradation is known to occur 
through the metabolism by dimethylarginine 
dimethylaminohydrolase (DDAH) enzymes into 
citrulline and amines.1,3,8,9 The fact shows that an 
increase in ADMA levels is closely associated 
with the risk of CVD in patients with CKD. 
Moreover, type I-PRMT enzymes play a major 
role in the production of ADMA. However, the 
mechanism of type I-PRMT on increased ADMA 
levels in patients with CKD remains unknown.
Our study was conducted to determine 
whether there was any gene polymorphism of 
type I-PRMT enzyme that may lead to increased 
ADMA levels in CKD patients. We expected 
that the results of study may be used to elaborate 
the molecular mechanisms of increased ADMA 
levels. If there is genetic polymorphism of 
type-I PRMT enzyme, which plays a major 
role in ADMA production; then the definitive 
management therapy can be determined to 
reduce ADMA levels. The study also tried to 
disclose molecular mechanisms underlying 
increase of ADMA in patients with end-stage 
kidney disease. Since the ADMA synthesis is 
primarily carried out by type I-PRMT enzymes, 
the authors hypothesized that there was a 
polymorphism of type I PRMT gene that may 
lead to increased ADMA levels in patients with 
CKD. To test the hypothesis, in addition to 
performing PCR on blood samples of patients 
with CKD, we also examined ADMA levels in 
the same patients; therefore, we can identify the 
association between elevated ADMA levels and 
type I-PRMT enzyme gene polymorphism.
METHODS
We conducted a cross-sectional study to 
determine the genetic polymorphism of PRMT-I 
enzyme and ADMA levels in hemodialysis 
(HD) patients. The study took place at Al-Irsyad 
Hospital and Institute of Tropical Disease, 
Airlangga University, Surabaya. The study 
population was patients undergoing regular HD 
in Al-Irsyad Hospital and Institute of Tropical 
Disease, Airlangga University Surabaya. The 
samples were patients who met the inclusion 
criteria. Sample size was all populations that 
met the inclusion criteria during the study or 
total population sampling. Inclusion criteria 
were men/women aged 18-65 years, who were 
undergoing regular/sustainable HD for three 
months/more, stable, having Hb >8g/dL and 
albumin >3 mg/dL, not taking drugs containing 
antioxidants in the last one month period, and 
have agreed and completed the informed consent 
form. Exclusion criterion was a blood transfusion 
prior to sampling.
To determine PRMT-1 gene polymorphism, 
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we performed blood sampling, DNA extraction, 
DNA amplification with PCR, and detection of 
PCR products by electrophoresis. Two percent 
agarose gel that had been made previously 
containing ethidium bromide was placed in 
a gel electrophoresis apparatus, added with 
TBE buffer 1 x until the gel was completely 
submerged. A marker, as much as 10 ml, was 
mixed by pipetting gently with 10x loading 
buffer of 2 ml that had been dripped on parafilm. 
From the first round PCR products, as much as 7 
ml was taken and mixed by gently pipetting with 
10x loading buffer of 2 ml that had been dripped 
on parafilm. Each of PCR product mixture was 
inserted into the gel slot. Gel electrophoresis 
apparatus was closed and run with 100 volts for 
about 30 minutes. Subsequently, it was observed 
under short-wave ultraviolet light. The observed 
results were documented with gel doc.
DNA Isolation and Purification with Low 
Melting Agarose
DNA bands appeared white on electrophoresis 
with 2% agarose S gel. Moreover, electrophoresis 
was repeated using low melting agarose gel 
(L). Two percent agarose L gel containing 
ethidium bromide was prepared, then a mixture 
of 15 mLDNA and 10 x 2 ml loading buffer was 
made. This mixture was applied to the gel wells 
with intervals without the use of markers and 
subsequently, the electrophoresis instrument was 
run. Electrophoresis results were observed with 
long-wave ultraviolet light. Gel containing DNA 
was isolated by cutting using a cutter that was 
washed each time of cutting. Gel slices were put 
into a sterile Eppendorf tube 1.5 mL. Then, we 
carried out DNA purification of PCR products 
from agarose L using QiaQuick Gel extraction 
Kit (Qiagen, Inc.. Cat. no. 28704).
PCR for Sequencing Preparation
Labeling with PCR for sequencing was 
performed by using the ready reaction cycle 
sequencing kit (ABI prism big dye terminator 
VII, applied biosystems). Sequencing reaction 
with a total volume of 20 mL was made in a 
sterile microcentrifuge tube with composition 
of: DNA from PCR results of 5 ml, sense or 
antisense primer of 4 pmol/mL for HBV; 1.5 ml 
(PRMT primer), 2 ml Ready reaction mixture Big 
Dye Terminator, 7 ml Buffer Big Dye, 4.5 ml DW, 
mixed by gently pipetting. Subsequently, they 
were poured into PCR machine that had been 
set to a temperature of 96°C for 3 min. PCR was 
performed for 25 cycles. Each cycle consisted 
of four stages: denaturation for 10 seconds in 
a temperature of 96°C, annealing for 5 seconds 
at 50°C, extension for 4 minutes at 60°C. Once 
the cycle was complete, the temperature was 
cooled to 4°C.
Purification and Precipitation of PCR Products 
for DNA Sequencing Preparation with Sodium 
Acetate-ethanol
Tube containing 20 m l  sequencing 
reaction was removed from the PCR machine. 
Subsequently, it was aspirated and transferred 
into a 1.5 ml sterile Eppendorf tube. Then, 2.5 
ml sodium acetate and 50 ml absolute ethanol 
were added to 1.5 ml sterile Eppendorf tubes, 
and mixed by flicking the tube. The mixture was 
incubated at room temperature for 5 minutes. 
Then, it was centrifuged at 15,000 rpm for 15 min 
at 4°C. The existing supernatant was carefully 
aspirated and discarded into a container. As 
much as 100 ml of 70% ethanol was added into 
the 1.5 mL Eppendorf tube. It was centrifuged 
once more at 15,000 rpm for 5 min at 4°C. Again, 
the supernatant was carefully aspirated and 
discarded into containers. Open tubes containing 
DNA pellets were wrapped in a plastic wrap 
and dried using a vacuum pump for 15 minutes. 
Thereafter, the dried DNA pellet were stored at 
a temperature of 4°C and to avoid the direct rays 
it was closed tightly with aluminum foil.
DNA Sequencing
DNA sequencing was performed using 
ABI prism 310 genetic analyzer (applied 
biosystems). DNA mixture had been prepared 
before sequencing. HiDiformamide (applied 
biosystems) as much as 25 mL was added to tubes 
containing dried DNA pellet. It was vortexed 
and incubated at a temperature of 95°C for 2 
min. Then, it was incubated in ice for about 3 
minutes and subsequently spinned-down. The 
tube remained stored in ice until it was ready 
to be analyzed. Moreover, it was aspirated and 
transferred into a sterile microtube specifically 
for sequencing. The tube was inserted into a 
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sequencer machine and run on a ABI prism 310 
genetic analyzer.
RESULTS
In this study, samples were taken from 
Hemodialysis Unit, Al-Irsyad Hospital, Surabaya. 
The study was conducted between May and 
September 2013. There were 57 samples that 
met the inclusion criteria.
Table 1. Subject characteristics
Variables n (%)
Sex
 - Male 39 (68.4%)
 - Female 18 (31.6%)
CKD Stage 
 - Stage IV 14 (24.6%)
 - Stage V 43 (75.4%)
Mean of blood pressure 
 - Systolic 160±2.5 mmHg
 - Diastolic 100±5.3 mmHg
Mean of age 55.4
normal ADMA
increase ADMA
Figure 1. Distribution of ADMA levels in CKD-hemodialysis 
patients















Figure 2. Mean difference of ADMA level in each stage
The first stage was the measurement of 
ADMA levels using ELISA. Of the 57 samples, 
there were 3 samples (5.6%) with normal range 
of ADMA levels (0.24 to 0.58 mmol/l) and 54 
(95.4%) samples with increased ADMA levels.
Sequencing was performed in 13 samples 
with elevated ADMA levels. The sequencing 
results showed that there was a suspected 
occurrence of PRMT-1 gene polymorphism, 
which was at sequence 5837 as we found 
Figure 3. A-D. Results on detection of PCR products by electrophoresis
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differences between genotype C and G at the 
sequence (Figure 5). Therefore, we performed 
DNA sequencing in the other 44 samples in order 
to obtain clearer profile about the location of 
PRMT-1 gene polymorphisms.
DISCUSSION
Asymmetric dimethyl arginine (ADMA) is 
an endogenous molecule that can be detected in 
human blood and urine. ADMA blood samples 
are stable for 24 hours at 2°-8°C or for 24 months 
if it is frozen at -20°C. In addition to being 
stable, ADMA is easily measured. It also reflects 
the concentration of NO and pathobiologically 
and directly contributes to the incidence of 
endothelial dysfunction. ADMA levels in 
vascular endothelium is ten times higher than 
those in plasma and the highest levels are found 
in kidney and spleen. Normal ADMA levels in 
humans is 0.24 to 0.58 mmol/l or 80-150 ng/ml. 
Measurement of serum ADMA is performed 
quantitatively using enzyme immunoassay 
ADMA®-ELISA.
It has been observed that ADMA has an 
important role in endothelial dysfunction and it 
may increase in the early stages of CKD.6 CKD 
Figure 4. Results of DNA sequences
Figure 5. Suspected location of polymorphism
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has become one of risk factors of CVD10 and 
ADMA has been considered as the link between 
CKD and CVD.1 The association between 
ADMA with CVD has been widely investigated 
in several studies. It has been recognized that 
ADMA infusion in healthy subjects decreases 
cardiac output and increases vascular resistance 
and blood pressure. Miyazaki et al. reported a 
significant positive correlation between ADMA 
plasma levels with the thickness of carotid 
artery intima, which can serve as a marker of 
arteriosclerosis. ADMA can also lower heart rate 
and cardiac output. It can inhibit angiogenesis, 
and increase atherogenesis. An in vitro study 
demonstrates that it may also accelerate the 
aging process of endothelial dysfunction. 
High concentration of ADMA can inhibit the 
movement of endothelial progenitor cell (EPC) 
from the bone marrow to damaged endothelial 
area. Furthermore, ADMA inhibition can 
increase the expression of vascular endothelial 
growth factor (VEGF) in endothelial cells and 
increase tube formation.3,7,8,11
Intensive research on molecular and cellular 
mechanisms that lead to atherogenesis has 
produced an understanding that vascular 
endothelium plays an important role to functional 
changes in the early stages of the vascular 
wall, which in turn initiates and exacerbates 
atherogenic process.12 It has been found that 
the main cause of NOS pathway disorder is the 
presence of endogenous NOS inhibitors, the 
ADMA and N mono methyl arginine (NMA). 
ADMA plasma levels is ten times greater than 
MMA levels.8,9 ADMA levels on vascular 
endothelium is ten times greater than the levels 
in plasma. Moreover, the highest levels are found 
in kidney and spleen.8
ADMA is synthesized in the cytoplasm 
of the cell and subsequently released into 
extracellular compartment and blood plasma. 
Dimethyl arginine is formed during proteolysis 
of methylated proteins. Protein methylation is 
a mechanism of post-translational modification 
of proteins contained in the body’s cells. This 
process causes a change in the tertiary structure 
and the function of proteins. Proteolysis is 
catalyzed by the enzyme S-adenoylmethionine 
protein N-methyltransferases (protein arginine 
methyltransferases/PMRT). Protein arginine 
methyltransferases I and II remove one or 
more methyl groups from the methyl donor 
S-adenosilmethionine to L-arginine residues in 
the protein or polypeptide. ADMA is formed 
through the activity of PMRT I, depending on 
the number of removed methyl groups; while 
the Symmetric Dimethyl Arginine (SDMA) is 
formed through the activity of PMRT II.3,8
There are several theories regarding the 
suspected cause of increased ADMA levels. 
Some experimental animal studies suggest that 
there may be a decrease of DDAH enzyme 
expression. Moreover, it was found that PRMT-I 
enzyme inhibition in animals had lowered the 
ADMA levels.1,8 However, the exact molecular 
mechanism on increased ADMA levels in CKD 
patients remains unknown.
The results obtained from this study were 
in accordance with previous findings, i.e. we 
found increased ADMA levels in CKD patients. 
In CKD, asymmetric increase of dimethyl 
arginine (ADMA) may occur due to increased 
production of ADMA by protein arginine 
methyltransferases (PRMT-1) or through the 
inhibition of ADMA elimination by either 
dimethylaminohidrolasedimethylarginine 
(DDAH) or kidneys. In chronic kidney disease 
(CKD), ADMA levels is found to be increased 
by about 30-40% and there is no correlation 
with creatinine serum levels and the stage of 
CKD. Other studies revealed that the higher 
the CKD stages, the higher the ADMA level. In 
LDL oxidation, the release of ADMA has also 
been increased significantly. Oxidative stress, a 
condition that can occur in patients with CKD, 
is associated with ADMA synthesis via the 
stimulation of enzymes PRMT1.3,8,9
CONCLUSION
Of 57 hemodialysis patients with stage IV-V, 
there were as many as 54 patients (95.4%) who 
had increased ADMA levels; while three patients 
(5.6%) had ADMA levels between the normal 
range. PRMT-1 gene polymorphism may occur at 
sequence 5837. Further research should be carried 
out on the sequencing process with higher number 
of samples in order to obtain a better profile about 
the site of PRMT-1 gene polymorphisms and 
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to determine the association of PRMT-1 gene 
polymorphism and ADMA level.
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